AACR 2023 | Comparing continuous and fixed duration therapy in CLL
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses factors that influence whether a patient with chronic lymphocytic leukemia (CLL) should receive continuous or fixed duration therapy. In the front line setting, continuous therapy consists of ibrutinib, acalabrutinib, or zanubrutinib, whereas fixed therapy consists of venetoclax or obinutuzumab. Disease features, co-morbidities, and the risk of hypertension and atrial fibrillation as a result of taking these BTK inhibitors all play a role in the decision-making process. The personal preference of the patient additionally can be taken into account. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
